{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-21-024728","form_type":"8-K","ticker":"AUPH","cik":"0001600620","company_name":"Aurinia Pharmaceuticals Inc.","filed_at":"2021-12-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.225467+00:00","generated_at":"2026-06-28T02:26:55.547517+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aurinia reports positive long-term safety data from AURORA 2 study of LUPKYNIS in lupus nephritis","bullets":["116 voclosporin-treated patients showed stable mean eGFR over 36 months; +2.7 mL/min increase from baseline vs control.","Serious adverse event rates lower in voclosporin group (19% vs 24% control); no deaths vs 4 in control.","Mean UPCR lower in voclosporin group at all time points over three years.","Withdrawal rate lower in voclosporin group (12.9% vs 15.0% control); drug well tolerated overall."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-21-024728","json":"https://secwatch.observer/filing/0001628280-21-024728.json","markdown":"https://secwatch.observer/filing/0001628280-21-024728.md","text":"https://secwatch.observer/filing/0001628280-21-024728.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1600620/000162828021024728/0001628280-21-024728-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1600620/000162828021024728/auph-20211209.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T02:26:55.547517+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}